{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:21:20Z","timestamp":1787800880540,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1053\/j.seminoncol.2009.10.012","type":"journal-article","created":{"date-parts":[[2009,12,5]],"date-time":"2009-12-05T04:11:38Z","timestamp":1259986298000},"page":"S37-S45","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S3","title":["Temsirolimus in Mantle Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes"],"prefix":"10.1053","volume":"36","author":[{"given":"Georg","family":"Hess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Berkenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.10.012_bib1","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428190701851364","article-title":"Therapeutic options in mantle cell lymphoma","volume":"49","author":"Gill","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.2008.19.5032","article-title":"Progress in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib6","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib7","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies","volume":"19","author":"Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","article-title":"Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib11","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib12","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib13","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib14","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib16","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib17","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib19","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib20","doi-asserted-by":"crossref","DOI":"10.3109\/10428190903207548","article-title":"Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies","author":"Coiffier","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib21","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/sj.onc.1210346","article-title":"Oncogenic tyrosine kinase NPM\/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway","volume":"26","author":"Marzec","year":"2007","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib22","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","article-title":"Syk-dependent mTOR activation in follicular lymphoma cells","volume":"108","author":"Leseux","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","article-title":"Molecular basis of mantle cell lymphoma","volume":"124","author":"Bertoni","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11864-006-0038-1","article-title":"Inhibition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway in hematologic malignancies","volume":"7","author":"Witzig","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ctrv.2006.10.004","article-title":"Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma","volume":"33","author":"Costa","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib29","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib32","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib35","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib36","doi-asserted-by":"crossref","first-page":"44a","DOI":"10.1182\/blood.V110.11.121.121","article-title":"A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL) [abstract 121]","volume":"110","author":"Reeder","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib38","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1158\/0008-5472.CAN-04-4180","article-title":"Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum","volume":"65","author":"Wlodarski","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2174\/157018007780077435","article-title":"mTOR inhibition in lymphoma: a rational and promising strategy","volume":"4","author":"Smith","year":"2007","journal-title":"Lett Drug Design Discov"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157488707780599366","article-title":"Clinical development of mTOR inhibitors: a focus on lymphoma","volume":"2","author":"Smith","year":"2007","journal-title":"Rev Recent Clin Trials"},{"issue":"suppl 15S","key":"10.1053\/j.seminoncol.2009.10.012_bib41","first-page":"457s","article-title":"Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes [abstract 8514]","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol, 2008 ASCO Annual Meeting Proceedings"},{"issue":"suppl 18S","key":"10.1053\/j.seminoncol.2009.10.012_bib42","article-title":"Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma [abstract 8055]","volume":"25","author":"Johnston","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib44","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.012_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00277-008-0582-9","article-title":"A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL","volume":"88","author":"Decker","year":"2008","journal-title":"Ann Hematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T22:34:13Z","timestamp":1590273253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409001948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":45,"alternative-id":["S0093775409001948"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.10.012","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}